Navigation Links
PAREXEL Corporate Vice President Dr. Alberto Grignolo Receives Lifetime Achievement Award From Good Clinical Practice Journal
Date:10/23/2008

BOSTON, Oct. 23 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, today announced that Alberto Grignolo, Ph.D., Corporate Vice President, PAREXEL Consulting, has received a Lifetime Achievement Award from the Good Clinical Practice Journal (GCPj). Dr. Grignolo was honored at the GCPj Awards ceremony, recognizing excellence in clinical research, which was held October 22, 2008 at the Banqueting House in London, England.

According to Helena Jensen, Publisher of the Good Clinical Practice Journal, "GCPj's Lifetime Achievement Award is presented to an exceptional individual with a distinguished career in the field of clinical development. We are pleased to honor Dr. Grignolo, who exemplifies dedication to advancing critical aspects of our industry, and whose achievements are especially notable for being consistently forward looking and visionary, from the championing of personalized medicine to his current role on the Executive Committee of the Clinical Trials Transformation Initiative."

"This honor from the GCPj readership and global clinical development community is for me not an end but rather a new beginning. This recognition is a challenge to inspire others to pursue our shared mission to prevent and cure disease, while continuing to improve the clinical trial enterprise and worldwide standards and practices to benefit patients. Together, through the important work that we do, we can promote innovation, help make personalized therapy a reality in our lifetime, meet urgent medical needs, insist on integrity and ethical behavior, and improve patient access to treatments," said Dr. Grignolo.

With more than 26 years of experience in regulatory and development strategy, Dr. Alberto Grignolo has helped numerous companies manage business risk by promoting effective regulatory strategies and relationships with regulators. Leading a global team of experts at PAREXEL Consulting, Dr. Grignolo oversees the management of regulatory submissions for clients with Regulatory Authorities worldwide. Dr. Grignolo has been an advocate for progress in personalized drug development, and has helped the industry recognize emerging opportunities to deliver safe and effective medicines to the right patients. Prior to joining PAREXEL, Dr. Grignolo served as President of FIDIA Pharmaceutical Corporation, and held management positions in regulatory affairs at Smith Kline & French Laboratories. He has served as an adviser to the Institute of Medicine of the National Academy of Sciences on human subject protection in clinical trials. He is currently a member of the Executive Committee of the Clinical Trials Transformation Initiative (CTTI). Dr. Grignolo has served as a leader of several industry organizations, including as Chairman of RAPS and on the Board of Directors for DIA. Dr. Grignolo holds a Ph.D. in Psychology from the University of North Carolina at Chapel Hill and a B.S. degree from Duke University. He completed postdoctoral work in neuropharmacology at Duke University Medical Center. He is currently Adjunct Associate Professor at the Massachusetts College of Pharmacy and Health Sciences.

Good Clinical Practice Journal (GCPj) (http://www.gcpj.com) addresses the regulatory, strategic, and clinical issues that directly impact clinical studies globally.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 69 locations throughout 52 countries around the world, and has approximately 8,800 employees. For more information about PAREXEL International visit http://www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including ClinPhone; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the Fiscal Year ended June 30, 2008 as filed with the SEC on August 28, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward- looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

Contacts:

Jennifer Baird, Senior Director of Rebecca Passo

Public Relations

PAREXEL International SHIFT Communications

Tel: +781-434-4409 Tel: +617-779-1817

Email: Jennifer.Baird@PAREXEL.com Email: rpasso@shiftcomm.com


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average
2. PAREXEL International to Present at William Blair Small-Cap Growth Stock Conference
3. PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors
4. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
5. PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back
6. PAREXEL Closes the Acquisition of ClinPhone
7. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
8. PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer
9. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2008 Earnings Release and Conference Call
10. PAREXEL International Updates Earnings Guidance in Conjunction with Its Investor Day
11. PAREXEL Expands Global Clinical Logistics Capabilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... , May 2, 2016 Q ... its technology partner Mannin Research Inc. will be attending ... which takes place from May 1-5, 2016 in ... be meeting with its vendors and research partners. The ... development goals and other collaborative opportunities for the MAN-01 ...
(Date:5/2/2016)... ... 2016 , ... F.E.E.D. Co., the Feline Environmental Enrichment Design ... product for indoor cats. The NoBowl Feeding System replaces the bowl with the ... nature intended. NoBowls make cats happy and healthy. , Since being introduced on ...
(Date:4/29/2016)... ... April 29, 2016 , ... Amendia, Inc., a leading ... today announced the completion of a significant transaction and partnership that positions Amendia ... and partners. Kohlberg & Company, L.L.C. (“Kohlberg”), a leading private equity firm ...
(Date:4/29/2016)... KY and San Diego, CA (PRWEB) , ... April 29, 2016 ... ... National Stem Cell Foundation (NSCF) to support the development of a patient-specific stem cell ... Dr. Andrés Bratt-Leal in the lab of Dr. Jeanne Loring at The Scripps Research ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/21/2016)... March 22, 2016 Unique ... passcodes for superior security   ... provider of secure digital communications services, today announced it ... and offer enterprise customers, particularly those in the Financial ... and voice authentication within a mobile app, alongside, and ...
Breaking Biology News(10 mins):